The Ezetrol controversy and New Year's resolutions will spark new emphasis on treating lipids

The Ezetrol controversy and New Year's resolutions will spark new emphasis on treating lipids...especially when combo therapy is needed.

We know statins are first-line for lowering LDL and cardiac risk.

But they don't always get patients to their lipid goals. And experts differ about what to do when a statin isn't enough.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote